Creative Planning
SGMO

Creative Planning’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Creative Planning’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-400
Closed -$1K – 2119
2020
Q1 		$1K Buy
+400
New +$2.97K ﹤0.01% 1855

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Creative Planning's SGMO Position: Q1 2026 in Review

Creative Planning increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 15% in Q1 2026, buying an estimated $792 and bringing the position to 14,840 shares worth $3.66K. The position accounts for ﹤0.01% of the portfolio, ranked #4085.

Creative Planning first reported a position in SGMO in Q3 2013 and has held it in 37 quarters since. The position peaked at $3.67M in Q4 2019. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Creative Planning held 14,840 shares of SANGAMO THERAPEUTICS INC worth $3.66K as of Q1 2026.
  • Creative Planning bought 1,990 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $792.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #4085 holding.
  • Creative Planning first reported a position in SANGAMO THERAPEUTICS INC in Q3 2013 and has held it in 37 quarters since.
  • Creative Planning's SANGAMO THERAPEUTICS INC position peaked at $3.67M in Q4 2019.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.